MCC-Modified Daunorubicinol
≥98%
- Product Code: 108900
CAS:
721945-30-8
| Molecular Weight: | 776.79 g./mol | Molecular Formula: | C₃₉H₄₄N₄O₁₃ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | 2-8°C, sealed, dry |
Product Description:
MCC-Modified Daunorubicinol is primarily used in the field of oncology, specifically for the treatment of certain types of cancer. It is a modified form of daunorubicinol, which is an active metabolite of daunorubicin, a well-known chemotherapeutic agent. The modification with MCC (a carboxymethylcellulose derivative) enhances its stability and targeting efficiency, making it more effective in delivering the drug to cancer cells while minimizing damage to healthy tissues.
This compound is particularly effective in treating hematologic malignancies, such as acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). It works by intercalating into DNA, thereby inhibiting the replication of cancer cells and inducing apoptosis. The MCC modification also helps in reducing the cardiotoxicity commonly associated with anthracycline drugs, making it a safer option for long-term treatment.
Additionally, MCC-Modified Daunorubicinol is being explored for use in targeted drug delivery systems. Its ability to bind specifically to cancer cells allows for a more precise and efficient treatment, potentially reducing the side effects and improving patient outcomes. Research is ongoing to expand its applications to other types of cancer and to further optimize its therapeutic efficacy.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.001 | 10-20 days | ฿72,000.00 |
+
-
|
MCC-Modified Daunorubicinol
MCC-Modified Daunorubicinol is primarily used in the field of oncology, specifically for the treatment of certain types of cancer. It is a modified form of daunorubicinol, which is an active metabolite of daunorubicin, a well-known chemotherapeutic agent. The modification with MCC (a carboxymethylcellulose derivative) enhances its stability and targeting efficiency, making it more effective in delivering the drug to cancer cells while minimizing damage to healthy tissues.
This compound is particularly effective in treating hematologic malignancies, such as acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). It works by intercalating into DNA, thereby inhibiting the replication of cancer cells and inducing apoptosis. The MCC modification also helps in reducing the cardiotoxicity commonly associated with anthracycline drugs, making it a safer option for long-term treatment.
Additionally, MCC-Modified Daunorubicinol is being explored for use in targeted drug delivery systems. Its ability to bind specifically to cancer cells allows for a more precise and efficient treatment, potentially reducing the side effects and improving patient outcomes. Research is ongoing to expand its applications to other types of cancer and to further optimize its therapeutic efficacy.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :